Soffer E E, Metcalf A, Launspach J
Department of Internal Medicine, University of Iowa, Iowa City.
Dig Dis Sci. 1994 May;39(5):929-33. doi: 10.1007/BF02087539.
To assess the efficacy of misoprostol in the treatment of patients with severe chronic constipation, nine such patients were enrolled in a double-blind, randomized, crossover study of misoprostol (1200 micrograms/day) or placebo, that lasted three weeks. During this period each patient received the drug for one week and placebo for another with a week washout period in between. A colonic transit study, using radiopaque markers, was performed during each of the treatment weeks, while the number of stools and their total weight was recorded by each patient for the appropriate periods. Colonic transit time was significantly and consistently decreased by misoprostol compared to placebo [66 hr +/- 10.2 vs 109.4 hr +/- 8.1 (P = 0.0005)]. Misoprostol significantly increased the total stool weight per week [976.5 g +/- 288.8 vs 434.6 g +/- 190.5 (P = 0.001)] and also significantly increased the number of stools per week compared to placebo [6.5 +/- 1.3 vs 2.5 +/- 0.11 (P = 0.01)]. The incidence of abdominal pain was similar in both groups. We concluded that misoprostol, during a short trial period, proved effective in increasing the frequency and weight of bowel movements and decreasing colonic transit time in patients with severe chronic constipation. It may be used as a therapeutic measure to treat such patients.
为评估米索前列醇治疗严重慢性便秘患者的疗效，9例此类患者参与了一项米索前列醇（1200微克/天）或安慰剂的双盲、随机、交叉研究，该研究持续3周。在此期间，每位患者接受药物治疗1周，接受安慰剂治疗1周，中间有1周的洗脱期。在每个治疗周期间，使用不透X线标志物进行结肠转运研究，同时每位患者记录相应时间段内的粪便次数及其总重量。与安慰剂相比，米索前列醇使结肠转运时间显著且持续缩短[66小时±10.2 vs 109.4小时±8.1（P = 0.0005）]。米索前列醇显著增加每周粪便总重量[976.5克±288.8 vs 434.6克±190.5（P = 0.001）]，与安慰剂相比，每周粪便次数也显著增加[6.5±1.3 vs 2.5±0.11（P = 0.01）]。两组腹痛发生率相似。我们得出结论，在短期试验期间，米索前列醇被证明可有效增加严重慢性便秘患者的排便频率和重量，并缩短结肠转运时间。它可作为治疗此类患者的一种治疗措施。
